Neurology in Utah

Epitel, Inc. is a digital health company based in Salt Lake City, Utah, specializing in innovative wearable EEG monitoring technology for brain health. Founded in 2008, Epitel developed the REMI™ Remote EEG Monitoring System, an FDA-cleared (2021) wireless, wearable sensor platform designed for seizure detection and electrographic monitoring in both hospital and ambulatory settings. The system features single-channel, high-fidelity EEG recordings with rapid setup (minutes), wireless operation enabling patient mobility, and integration with standard EEG review platforms like Persyst™ Mobile for remote clinician review. REMI Vigilenz™ AI for Event Detection augments clinical review by automatically identifying potential electrographic seizure activity with confidence scoring. The platform is clinically validated, reimbursable under existing codes, and suitable for adult and pediatric patients (1+ years for monitoring; 6+ years for AI analysis). Epitel's technology addresses critical care, emergency department, and outpatient epilepsy monitoring needs. The company has secured over $20 million in funding and brings extensive expertise in medical device development, neural engineering, and regulatory affairs.

Blackrock Neurotech is a medical device company specializing in brain-computer interface (BCI) technologies for patients with paralysis, ALS, blindness, and other neurological disorders. Founded in 2008, the company has conducted over 19 years of human studies and accumulated more than 30,000 days of implant research. Core technologies include implantable microelectrode arrays (Utah Array) that decode neural signals, enabling users to control computers, robotic arms, and prosthetics through thought alone. The MoveAgain BCI platform is designed for clinical use to enhance patient independence and restore function. Blackrock Neurotech supports over 1,000 research institutions worldwide with neurotechnology devices and research solutions, with documented achievements in neuroprosthetics demonstrating significant improvements in patient quality of life and functional capabilities.

Novarad Corp is a medical software and digital imaging solutions company headquartered in Provo, Utah, with over 30 years of innovation in enterprise medical imaging. The company specializes in PACS (Picture Archiving and Communication Systems), enterprise imaging, and augmented reality surgical navigation. Novarad's product portfolio serves hospitals ranging from 26 to 500+ bed facilities, critical access hospitals, rural hospitals, imaging centers, and clinics. Core offerings include NovaPACS with Enterprise Imaging (customizable PACS platform with HL7 integration capabilities), VisAR (FDA-approved fully immersive 3D augmented reality surgical navigation system for spine and cranial neurosurgery), MobileRad 360 (mobile EMR ecosystem), Nova RIS (radiology information system), CryptoChart (medical image sharing), NovaCardio (cardiology solutions), and MammoIQ (mammography software). The company supports cloud, on-premises, edge, and hybrid deployment models. Novarad maintains strategic partnerships with major healthcare IT vendors including eClinicalWorks, NextGen, Medent, and others. The company is known for USA-based 24/7 customer support and implementation services. VisAR has received FDA clearance for precision spine surgery and regulatory approval in Indonesia for stereotactic spine surgery. The company demonstrates expertise in enterprise imaging interoperability, workflow optimization, and specialized imaging across radiology, cardiology, and mammography.

Rezzimax, LLC manufactures the Rezzimax Pain Tuner, a non-invasive, handheld neurological device designed to stimulate the vagus nerve and central nervous system through variable vibration frequencies. The device is intended to improve nerve function, enhance blood flow to affected areas, and support natural pain relief and symptom management. Clinical applications include treatment of TMJ/TMD, sinus congestion, neck pain, chronic pain, neuropathic conditions (post-herpetic neuralgia), Parkinson's disease symptom management, and recovery of sensory function (anosmia). The company offers two primary product lines: the Rezzimax Tuner Pro II, a full-featured model with specialized attachments (oral accessory, tongs, soft brain tip) for targeted application, and the Rezzimax Tuner Mini, a compact, travel-friendly variant with built-in timers. Both are assembled and engineered in Cache Valley, Utah. The company maintains FDA registration and operates a direct-to-consumer model with a 60-day money-back guarantee. Products are marketed for both professional clinical integration and at-home personal use. Rezzimax holds FDA certification confirming product registration and quality compliance; ongoing FDA clinical studies and quality controls apply. The company emphasizes domestic manufacturing and has received recognition as part of the Coolest Thing Made in Utah 2020 initiative.

ANEclear is a patented medical device designed to accelerate the washout of inhaled volatile anesthetics from the brain at the end of surgery. The device uses the patient's own carbon dioxide to vasodilate cerebral vasculature and restore electrical signaling in neurons controlling wakefulness and breathing, enabling faster and safer anesthesia emergence. ANEclear is specifically indicated for elderly, obese, and pediatric patients at elevated risk for postoperative complications including delirium, postoperative cognitive dysfunction, airway obstruction, and nausea/vomiting. By rapidly reversing anesthetic effects in the brain, ANEclear reduces recovery time, lowers complications, and improves operating room and post-anesthesia care unit efficiency while reducing overall patient care costs.

BlueWind Medical manufactures Revi, an implantable neuromodulation device for the treatment of urge urinary incontinence (UUI). Revi is a miniature implant positioned near the ankle that delivers tibial nerve stimulation to modulate bladder control signals. The device is implanted during a single outpatient procedure under local anesthesia and offers personalized, patient-controlled therapy requiring as little as 30 minutes daily. Clinical data from the OASIS study (NCT03596671, 3-year follow-up) demonstrates 95% patient satisfaction and 79% of study completers achieving greater than 50% reduction in incontinence episodes. Revi represents a drug-free alternative to pharmacological and surgical interventions for overactive bladder. The company has received regulatory clearance and recognition, including the 2025 MedTech Breakthrough Award for Best New Technology Solution in Therapeutics. BlueWind's technology addresses a significant market of patients with urge incontinence, offering a reversible, minimally invasive solution with demonstrated long-term safety and efficacy profiles suitable for outpatient urology and continence specialty practices.